AZAD Pharma advances its Brinzolamide Brimonidine PF eye drops suspension with Silgan Dispensing’s Iridya® for Preservative-Free Eye Drops
Supporting preservative‑free eye care with microbiological integrity and patient‑friendly handling — backed by transparent, solution‑oriented collaboration.
Congratulations to AZAD Pharma on their approval of the Brinzolamide Brimonidine Preservative-free eye drops suspension in several EU countries! We are very proud to support their path forward with Iridya® and look forward to continuing to deliver exceptional experiences at every interaction for patients and partners alike.
AZAD Pharma developed its Brinzolamide Brimonidine Preservative-free eye drops suspension dossier with a clear goal for AZAD’s B2B customers: enable preservative-free eye care that supports microbiological integrity and easy, patient-friendly handling. In a highly competitive market, AZAD also sought a meaningful differentiator—particularly as a smaller organization facing heightened scrutiny from potential partners. A key requirement was selecting a multidose delivery system that would inspire confidence without compromising the user experience.
To achieve this, AZAD chose Iridya®, Silgan Dispensing’s preservative‑free multidose dropper. The look, feel, and technology of the Iridya® system were decisive advantages compared with competing solutions.
At the heart of AZAD’s Brinzolamide Brimonidine Preservative-Free approach is Iridya®, designed to support secure dosing and a clean, controlled user experience — drop after drop.
- Patient Friendly: A familiar squeeze-bottle design validated through qualitative testing with a tamper-evident safety seal for added security and an elongated dropper tip for precise application.
- Ergonomically Efficient: Low squeeze force combined with NO-JET Technology for clean, controlled dosing.
- Industry Trusted Performance: Designed and challenge-tested for preservative-free formulations with proven microbiological safety for 2 months.
Iridya® is more than just a multidose dropper — it delivers a reliable, preservative‑free experience designed around patient needs, drop after drop.
AZAD and Silgan Teams who worked on this Iridya project.
The project succeeded thanks to close alignment, transparent communication, and fast, solution‑oriented problem‑solving across both teams. As AZAD’s Torsten Müller, Head of R&D at AZAD, emphasized, “The collaboration across the development team was outstanding. Transparent communication, a solution-oriented mindset, and efficient execution throughout. Simply outstanding”
Explore more about AZAD Pharma, Iridya® and our commitment to your patients with these links: